ASMR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. حسب Xue Li (285380)

الموضوعات:

Each types of tuberculosis ASDR in 1990 and 2021. حسب Xue Li (285380)

الموضوعات:

Each types of tuberculosis ASIR in 1990 and 2021. حسب Xue Li (285380)

الموضوعات:

Death, ASMR, and Relative change of Tuberculosis in children and Adolescence in global and 21 regions, with EAPC from 1990 and 2021. حسب Xue Li (285380)

الموضوعات:

Incidence, death and DALYs of TB, by age and sex in 2021. حسب Xue Li (285380)

الموضوعات:

Composition ratio of each types of tuberculosis ASDR in 1990 and 2021. حسب Xue Li (285380)

الموضوعات:

Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021. حسب Xue Li (285380)

الموضوعات:

Composition ratio of each types of tuberculosis ASMR in 1990 and 2021. حسب Xue Li (285380)

الموضوعات:

DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021. حسب Xue Li (285380)

الموضوعات:

General characteristics of relative handgrip strength at baseline. حسب Yeo Ju Sohn (18536198)

الموضوعات:

This dataset includes detailed information for 22,016 individuals. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Flow diagram of participants meeting the inclusion and exclusion criteria. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

الموضوعات:

These files contain the STATA program codes used in the study. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Generalized estimating equation model covariance structure analysis. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Raw dataset collected from the KLoSA from 2006 to 2020. حسب Yeo Ju Sohn (18536198)

الموضوعات:

General characteristics of research participants. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Generalized estimation equation model analysis of diabetes mellitus incidence according to relative handgrip strength. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength. حسب Yeo Ju Sohn (18536198)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"